updated 12/2/2010 1:15:38 PM ET 2010-12-02T18:15:38

Management to Present at 1:30 PM PST / 4:30 PM EST

EMERYVILLE, Calif., Dec. 2, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will deliver a corporate presentation at the LD MICRO Growth Conference on Thursday, December 9th, 2010 at the Luxe Sunset Bel Air in Los Angeles. The presentation is scheduled for 1:30 PM PST / 4:30 PM EST.

To arrange a meeting with management, please contact Adam Holdsworth at the Investor Relations Group, 212-825-3210, or e-mail adam@investorrelationsgroup.com. 

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic, anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's Aganocide® compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital infections, chronic non-healing wounds, urinary catheter blockage and encrustation (UCBE) and onychomycosis. The company has a license and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications. For more information on NovaBay, visit: www.novabaypharma.com.

About LD Micro

LD MICRO is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by institutional investors. LD MICRO is a non-registered investment advisor.

CONTACT:  NovaBay Pharmaceuticals, Inc.
          Investors:
          Thomas J. Paulson, Chief Financial Officer
          510-899-8809
          tpaulson@novabaypharma.com

          The Investor Relations Group
          Investor Relations:
          Adam Holdsworth
            212-825-3210
            adam@investorrelationsgroup.com
          Public Relations:
          Laura Colontrelle
            212-825-3210
            laura@investorrelationsgroup.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 2.79%
$30K home equity loan FICO 5.78%
$75K home equity loan FICO 4.54%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.57%
13.57%
Cash Back Cards 17.91%
17.91%
Rewards Cards 17.15%
17.15%
Source: Bankrate.com